Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Novel new diabetes treatment fares well in clinical trials

Posted: August 27, 2014

Clinical trials on a novel new type 2 diabetes treatment lowered glucose, did not increase lipids, and was well tolerated in patients with the chronic disease.

Lipitor side effects lawsuits mount against Pfizer

Posted: August 27, 2014

Lawsuits are mounting against Pfizer Inc., alleging the company withheld information that its cholesterol-lowering statin drug Lipitor could cause women to develop type 2 diabetes. In the past five months, Lipitor side effects lawsuits have jumped from 56 to more than

Newborn head and body support products recalled due to presence of mold

Posted: August 26, 2014

Children’s Medical Ventures is recalling its Gel-E Donut and Squishon 2 products used in hospitals to support and cradle an infant’s head or body because of numerous complaints about visible mold on the outer surface of the products. The mold

Mirena IUD linked to increased breast cancer risk in premenopausal women

Posted: August 26, 2014

Premenopausal women who use a hormone-releasing intrauterine device, such as the Mirena IUD, are at greater risk of developing breast cancer, according to a study recently published in the journal Obstetrics & Gynecology.

Insulin therapy may help prevent acute pancreatitis

Posted: August 25, 2014

Acute pancreatitis affects about 20,000 people every year and results in 1,000 deaths. It can also increase the risk for pancreatic cancer, one of the most deadly forms of the disease. Yet, there is no immediate cure for the painful and

New testosterone replacement capsule fares well in clinical trials

Posted: August 25, 2014

Clinical trials for Clarus Therapeutic’s new testosterone replacement treatment Rextoro show the drug is comparable to other testosterone therapies and, if approved by the Food and Drug Administration (FDA), could provide patients with yet another treatment option to boost the

Bone marrow treatment restores hair growth in patients with alopecia

Posted: August 24, 2014

Clinical trials on FDA-approved drugs for other conditions have been shown to restore hair growth in some patients with alopecia areata, an autoimmune disease that causes hair loss.

Drug company tests new drug to boost testosterone levels in men

Posted: August 23, 2014

A new treatment designed to boost testosterone levels in men, which is not a testosterone replacement therapy, is currently being tested in clinical trials. If data is favorable, the drug could be considered for regulatory approval by the end of

Second transvaginal mesh lawsuit against Boston Scientific goes to trial

Posted: August 23, 2014

The second bellwether trial involving injuries from Boston Scientific’s transvaginal mesh device is underway in Massachusetts state court, and plaintiffs are hoping for a different outcome than the first.

Testosterone levels tend to fluctuate significantly in younger men but remain more constant in older men

Posted: August 22, 2014

Most schools of thought suggest that measuring testosterone levels in men can be tricky because the hormone levels vary from day to day as well as hour to hour. However, a new study finds that only young men experience statistically